十二指肠溃疡治疗市场－全球产业规模、份额、趋势、机会、预测：治疗方法、给药途径、通路、区域及竞争格局，2021-2031年

全球十二指肠溃疡治疗市场预计将从 2025 年的 53.1 亿美元成长到 2031 年的 68.5 亿美元，复合年增长率为 4.34%。

该市场涵盖质子帮浦阻断剂、抗生素和钾离子竞争性酸分泌抑制剂等治疗药物，旨在修復近端小肠黏膜损伤。主要成长要素包括非类固醇消炎剂(NSAIDs) 的广泛应用以及全球范围内需要持续药物治疗的细菌感染疾病负担。特别是，美国胃肠病学会 (AGA) 2024 年报告指出，成人幽门螺旋桿菌感染的粗略盛行率已达 43.9%，证实存在一个稳定的患者群体，需要根除治疗以预防溃疡復发和併发症。

儘管需求指标强劲，市场仍面临一个重大障碍：抗生素抗药性日益增强。这降低了标准治疗通讯协定的有效性。抗药性的上升迫使临床医生依赖更复杂的补救性治疗，使根除疾病变得更加困难。因此，广泛有效的疾病管理面临许多挑战，并可能限制第一线标准药物的持续使用。

市场驱动因素

日益增长的脆弱老年人口正成为全球十二指肠溃疡治疗市场的主要推动力，显着改变了患者群体结构，并持续推动对治疗方案的需求。随着老龄化，胃黏膜的天然防御能力下降，使老年人更容易受到胃酸和幽门螺旋桿菌感染的损害。老年人常见的合併症，例如关节炎，进一步加剧了这种易感性，并导致他们长期服用非类固醇消炎剂（NSAIDs），而NSAIDs正是溃疡形成的主要风险因素。根据联合国人口基金（UNFPA）的数据，截至2024年6月，65岁及以上人口将占世界人口的10.3%，需要积极抑酸或根除治疗以预防出血和穿孔等併发症的高风险患者群体正在迅速扩大。

同时，新型治疗药物的研发正在重振市场。这些药物克服了传统质子帮浦阻断剂（PPI）的局限性，尤其是在应对抗生素抗药性等问题方面。药厂正积极推出钾离子竞争性酸分泌抑制剂（P-CAB），与传统药物相比，这类药物起效较快，在酸性环境下稳定性较佳。此类药物的商业性成功显而易见；2024年5月，武田药品工业株式会社宣布，其P-CAB製剂「Takecab/Bocinti」在截至2024年3月的财年销售额达到1185亿日元，市场渗透率很高。此外，製造商正将目光投向新兴市场，以满足尚未被满足的医疗需求。例如，2024年8月，大隈製药将其新药fexprazan拓展至拉丁美洲市场，目标市场是墨西哥、智利和厄瓜多尔价值3亿美元的抗溃疡药物市场。这些创新提供了有效的替代方案，并在抗药性挑战下保持了市场价值。

市场挑战

抗生素抗药性日益严重的是全球十二指肠溃疡治疗市场面临的一大障碍，从根本上削弱了标准药物治疗方案的可靠性。传统的第一线疗法，例如质子帮浦阻断剂合併克拉霉素或甲硝唑，其临床疗效已显着下降，尤其是在幽门螺旋桿菌等细菌菌株对主要抗生素产生强抗药性的情况下。这种疗效的下降迫使医疗机构放弃高效的高剂量治疗方案，转而采用更复杂、更长期的替代疗法。因此，药物库存周转率变得难以预测，现有药物组合的商业性可行性也受到威胁，因为临床医生在未进行昂贵的药敏试验之前，不愿轻易开立标准抗生素疗程。

近期临床数据凸显了这些市场障碍的严重性，尤其强调了治疗失败的规模。根据美国胃肠病学会 (ACG) 2024 年的报告，在美国所有监测区域，克拉霉素的抗药性率已超过 20%。这项数据表明，相当一部分目标患者群体对最常用的经验性治疗不再有效。如此高的抗药性造成了不稳定的市场环境，无法保证标准药物的持续使用，阻碍了十二指肠溃疡治疗领域的整体进展。

市场趋势

幽门螺旋桿菌根除疗法中固定剂量复方製剂的普及正在改变市场格局，有效解决了患者难以坚持复杂多药联合治疗的重大难题。为了应对联合治疗克拉霉素三重疗法日益严重的抗药性问题，製药公司推出了一系列包含抗生素和抑酸剂的复方胶囊，旨在简化给药方案并提高杀菌效果。随着支付方逐渐认识到简化给药方案有助于避免治疗失败和后续补救治疗，这一趋势正获得商业性的成功。例如，2024年8月，Redhill BioPharma宣布其基于利福布汀的固定剂量组合药物Talicia已将处方笺覆盖范围扩大到美国约2500万受益人，这表明市场正明显转向简化的、以抗药性为重点的根除通讯协定。

同时，在治疗溃疡相关併发症（例如上消化道出血）方面，微创内视镜治疗性介入正显着兴起。先进的止血技术，例如内视镜夹和止血粉，正在取代传统的外科手术方法，提高治疗的精确度，并降低高风险出血性溃疡的併发症。新一代可视化系统的普及提高了对这些病变的检测和治疗能力，从而推动了医疗设备行业的显着收入成长。根据Olympus Corporation2024年5月发布的公告，EVIS X1内视镜系统的推出使其在北美的胃肠内视镜业务同比增长了20%，凸显了临床对先进治疗视觉化平台日益增长的需求。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：十二指肠溃疡治疗的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 治疗方法（质子帮浦阻断剂、H2受体拮抗剂、抗生素等）
  • 给药途径（口服、注射）
  • 分销通路（零售药局、医院药局、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美十二指肠溃疡治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲十二指肠溃疡治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区十二指肠溃疡治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲十二指肠溃疡治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲十二指肠溃疡治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球十二指肠溃疡治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Takeda
• AstraZeneca
• Pfizer
• GlaxoSmithKline
• Novartis
• Bayer
• Sanofi
• Johnson & Johnson
• Sun Pharma
• Cipla

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Duodenal Ulcer Treatment Market is projected to expand from USD 5.31 Billion in 2025 to USD 6.85 Billion by 2031, reflecting a CAGR of 4.34%. This market encompasses therapeutic agents like proton pump inhibitors, antibiotics, and potassium-competitive acid blockers designed to heal mucosal defects in the proximal small intestine. Key growth drivers include the widespread use of nonsteroidal anti-inflammatory drugs and the enduring global burden of bacterial infections requiring ongoing pharmaceutical management. Notably, the American Gastroenterological Association reported in 2024 that the crude global prevalence of Helicobacter pylori infection among adults stood at 43.9%, ensuring a consistent patient base needing eradication therapy to avert ulcer recurrence and complications.

Despite these robust demand indicators, the market faces a substantial obstacle in the form of increasing antimicrobial resistance, which diminishes the effectiveness of standard treatment protocols. This rising resistance compels clinicians to resort to more intricate salvage therapies and complicates successful eradication efforts. Consequently, this creates a significant hurdle to effective disease management on a broad scale and potentially restricts the consistent utilization of standard first-line pharmaceutical options.

Market Driver

The expansion of the vulnerable geriatric population acts as a primary catalyst for the Global Duodenal Ulcer Treatment Market, significantly reshaping patient demographics and fueling sustained demand for therapeutic solutions. As people age, natural defenses in the gastric mucosa weaken, rendering the elderly far more prone to damage from gastric acid and Helicobacter pylori infections. This susceptibility is further aggravated by the prevalence of comorbidities like arthritis in older adults, necessitating chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), which are major risk factors for ulceration. According to the United Nations Population Fund in June 2024, the global proportion of individuals aged 65 and older rose to 10.3%, creating a rapidly expanding base of high-risk patients requiring potent acid-suppression and eradication therapies to prevent complications such as bleeding or perforation.

Concurrently, the development of novel therapeutic agents is revitalizing the market by overcoming the limitations of traditional proton pump inhibitors (PPIs), especially regarding antibiotic resistance. Pharmaceutical firms are aggressively launching potassium-competitive acid blockers (P-CABs), which provide faster onset and superior stability in acidic conditions compared to conventional options. The commercial viability of this class is clear; Takeda Pharmaceutical Company Limited reported in May 2024 that sales of its P-CAB, Takecab/Vocinti, hit 118.5 billion JPY for the fiscal year ending March 31, 2024, showing strong adoption. Additionally, manufacturers are targeting emerging markets to address unmet needs; for instance, Daewoong Pharmaceutical expanded its novel agent Fexuprazan into Latin America in August 2024, aiming at an anti-ulcer market worth $300 million across Mexico, Chile, and Ecuador. These innovations offer effective salvage alternatives, maintaining market value despite resistance challenges.

Market Challenge

The escalating incidence of antimicrobial resistance poses a significant barrier to the Global Duodenal Ulcer Treatment Market by fundamentally compromising the reliability of standard pharmaceutical regimens. As bacterial strains, specifically Helicobacter pylori, build strong immunity to crucial antibiotics, the clinical effectiveness of traditional first-line therapies-usually involving proton pump inhibitors alongside clarithromycin or metronidazole-drops markedly. This decline in success rates obliges healthcare providers to move away from streamlined, high-volume prescription patterns toward more complicated, extended-duration salvage therapies. As a result, pharmaceutical inventory turnover becomes unpredictable, and the commercial viability of established drug combinations is jeopardized as clinicians become reluctant to prescribe standard antibiotic packs without costly susceptibility testing.

The gravity of this market impediment is highlighted by recent clinical data emphasizing the magnitude of therapeutic failure. According to the American College of Gastroenterology in 2024, resistance rates to clarithromycin were confirmed to reach or exceed 20 percent across all monitored regions in the United States. This statistic reveals that a significant portion of the target patient population is now unresponsive to the most frequent empiric treatments. Such elevated resistance levels generate a volatile market atmosphere where the consistent use of standard pharmaceutical products cannot be guaranteed, thereby stalling momentum within the broader duodenal ulcer treatment sector.

Market Trends

The proliferation of fixed-dose combination kits for H. pylori eradication is transforming the market by tackling the critical problem of patient non-adherence to complex multi-drug regimens. With resistance to standard clarithromycin-based triple therapies increasing, pharmaceutical developers are launching all-in-one capsules that merge antibiotics with acid suppressants to simplify dosing schedules and boost bactericidal potency. This trend is gaining commercial momentum as payers acknowledge the benefits of streamlined administration in averting treatment failure and subsequent salvage needs. For instance, RedHill Biopharma announced in August 2024 that its rifabutin-based fixed-dose combination, Talicia, achieved expanded formulary coverage for roughly 25 million lives in the United States, signaling a distinct market shift toward simplified, resistance-oriented eradication protocols.

Simultaneously, there is a marked shift toward minimally invasive endoscopic therapeutic interventions for managing ulcer-related complications like upper gastrointestinal bleeding. Advanced hemostatic technologies, such as through-the-scope clips and hemostatic powders, are superseding traditional surgical methods, enabling clinicians to treat high-risk bleeding ulcers with enhanced precision and reduced morbidity. The widespread implementation of next-generation visualization systems improves the detection and treatment of these lesions, driving substantial revenue growth in the device sector. According to Olympus Corporation in May 2024, its GI Endoscopy business in North America expanded by 20% year-over-year following the launch of the EVIS X1 endoscopy system, highlighting the growing demand for advanced therapeutic visualization platforms in clinical settings.

Key Market Players

• Takeda
• AstraZeneca
• Pfizer
• GlaxoSmithKline
• Novartis
• Bayer
• Sanofi
• Johnson & Johnson
• Sun Pharma
• Cipla

Report Scope

In this report, the Global Duodenal Ulcer Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Duodenal Ulcer Treatment Market, By Treatment

• Proton Pump Inhibitors
• H2 Antagonists
• Antibiotics
• Other

Duodenal Ulcer Treatment Market, By Route Of Administration

• Oral
• Parenteral

Duodenal Ulcer Treatment Market, By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Other

Duodenal Ulcer Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Duodenal Ulcer Treatment Market.

Available Customizations:

Global Duodenal Ulcer Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Duodenal Ulcer Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Proton Pump Inhibitors, H2 Antagonists, Antibiotics, Other)
  • 5.2.2. By Route Of Administration (Oral, Parenteral)
  • 5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Other)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Duodenal Ulcer Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Route Of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Duodenal Ulcer Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Route Of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Duodenal Ulcer Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Route Of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Duodenal Ulcer Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Route Of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Duodenal Ulcer Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Route Of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Duodenal Ulcer Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Route Of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Duodenal Ulcer Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Route Of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Duodenal Ulcer Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Route Of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Duodenal Ulcer Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Route Of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Duodenal Ulcer Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Route Of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Duodenal Ulcer Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Route Of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Duodenal Ulcer Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Route Of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Duodenal Ulcer Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Route Of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Duodenal Ulcer Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Route Of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Duodenal Ulcer Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Route Of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Duodenal Ulcer Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Route Of Administration
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Duodenal Ulcer Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Route Of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Duodenal Ulcer Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Route Of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Duodenal Ulcer Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Route Of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Duodenal Ulcer Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Route Of Administration
      • 9.3.3.2.3. By Distribution Channel

10. South America Duodenal Ulcer Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Route Of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Duodenal Ulcer Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Route Of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Duodenal Ulcer Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Route Of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Duodenal Ulcer Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Route Of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Duodenal Ulcer Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Takeda
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca
• 15.3. Pfizer
• 15.4. GlaxoSmithKline
• 15.5. Novartis
• 15.6. Bayer
• 15.7. Sanofi
• 15.8. Johnson & Johnson
• 15.9. Sun Pharma
• 15.10. Cipla

16. Strategic Recommendations

17. About Us & Disclaimer